Review article · 2012 · Open access
Challenges in Development of Nanoparticle-Based Therapeutics
The AAPS Journal, 14(2), 282–295 · Published 9 March 2012 · DOI 10.1208/s12248-012-9339-4
In brief
“Challenges in Development of Nanoparticle-Based Therapeutics” is a 2012 review article by Neil P. Desai, published in The AAPS Journal. OpenAlex counts 1,326 citations as of 20 November 2026, which puts it in the top 1% of works published in 2012 by citations. It is open access under a CC BY licence: the full text is free to read at The AAPS Journal.
- Citations
- 1,326
- Most cited in
- 2025 (239)
- Field-weighted impact
- 2.04
- References
- 89
- Authors
- 1
Abstract
In recent years, nanotechnology has been increasingly applied to the area of drug development. Nanoparticle-based therapeutics can confer the ability to overcome biological barriers, effectively deliver hydrophobic drugs and biologics, and preferentially target sites of disease. However, despite these potential advantages, only a relatively small number of nanoparticle-based medicines have been approved for clinical use, with numerous challenges and hurdles at different stages of development. The complexity of nanoparticles as multi-component three dimensional constructs requires careful design and engineering, detailed orthogonal analysis methods, and reproducible scale-up and manufacturing process to achieve a consistent product with the intended physicochemical characteristics, biological behaviors, and pharmacological profiles. The safety and efficacy of nanomedicines can be influenced by minor variations in multiple parameters and need to be carefully examined in preclinical and clinical studies, particularly in context of the biodistribution, targeting to intended sites, and potential immune toxicities. Overall, nanomedicines may present additional development and regulatory considerations compared with conventional medicines, and while there is generally a lack of regulatory standards in the examination of nanoparticle-based medicines as a unique category of therapeutic agents, efforts are being made in this direction. This review summarizes challenges likely to be encountered during the development and approval of nanoparticle-based therapeutics, and discusses potential strategies for drug developers and regulatory agencies to accelerate the growth of this important field.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Desai, N. P. (2012). Challenges in Development of Nanoparticle-Based Therapeutics. The AAPS Journal, 14(2), 282–295. https://doi.org/10.1208/s12248-012-9339-4
MLA 9
Desai, Neil P. “Challenges in Development of Nanoparticle-Based Therapeutics.” The AAPS Journal, vol. 14, no. 2, 2012, pp. 282–295. https://doi.org/10.1208/s12248-012-9339-4.
Chicago
Desai, Neil P. 2012. “Challenges in Development of Nanoparticle-Based Therapeutics.” The AAPS Journal 14 (2): 282–295. https://doi.org/10.1208/s12248-012-9339-4.
Harvard
Desai, N. P. (2012) ‘Challenges in Development of Nanoparticle-Based Therapeutics’, The AAPS Journal, 14(2), pp. 282–295. doi:10.1208/s12248-012-9339-4.
IEEE
N. P. Desai, “Challenges in Development of Nanoparticle-Based Therapeutics,” The AAPS Journal, vol. 14, no. 2, pp. 282–295, 2012, doi: 10.1208/s12248-012-9339-4.
BibTeX
@article{desai2012challenges,
title = {{Challenges in Development of Nanoparticle-Based Therapeutics}},
author = {Desai, Neil P.},
journal = {The AAPS Journal},
year = {2012},
volume = {14},
number = {2},
pages = {282--295},
doi = {10.1208/s12248-012-9339-4},
url = {https://doi.org/10.1208/s12248-012-9339-4}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 78 | |
| 2018 | 78 | |
| 2019 | 74 | |
| 2020 | 79 | |
| 2021 | 64 | |
| 2022 | 71 | |
| 2023 | 86 | |
| 2024 | 145 | |
| 2025 | 239 | |
| 2026 | 205 |
Its field-weighted citation impact is 2.04: it has been cited 2.04 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- nanotherapeutics
- nanomedicine development
- drug delivery
- hydrophobic drug delivery
- targeted drug delivery
- nanoparticle engineering
- nanomedicine safety
- tissue distribution
Work with this paper
Most-cited papers in Materials Science
- Electric Field Effect in Atomically Thin Carbon FilmsKostya S. Novoselov, Andre K. Geim, Sergey V. Morozov and 5 more · Science · 2004 · 67,474 citations
- Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenidesROBERT D. SHANNON · Acta Crystallographica Section A · 1976 · 66,944 citations
- Ab initio molecular dynamics for liquid metalsGeorg Kresse, J. Häfner · Physical review. B, Condensed matter · 1993 · 46,320 citations
- Helical microtubules of graphitic carbonSumio Iijima · Nature · 1991 · 43,639 citations
- The rise of grapheneAndre K. Geim, Kostya S. Novoselov · Nature Materials · 2007 · 40,328 citations
Questions about this paper
How do I cite this paper in APA style?
Desai, N. P. (2012). Challenges in Development of Nanoparticle-Based Therapeutics. The AAPS Journal, 14(2), 282–295. https://doi.org/10.1208/s12248-012-9339-4
How many times has this paper been cited?
1,326 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The AAPS Journal: sign in and open the PDF from this page.
Who wrote this paper?
Neil P. Desai.
What is the DOI of this paper?
10.1208/s12248-012-9339-4, permanently at https://doi.org/10.1208/s12248-012-9339-4. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.